Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

NCT07710885 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

784

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Futibatinib
DRUG: Zimberelimab
DRUG: Durvalumab
DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Taiho Pharmaceutical Co., Ltd.

Collaborators

[object Object]